8-OH-DPAT (8-Hydroxy-DPAT)

製品コードS8447 バッチS844701

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C16H25NO
分子量 247.38 CAS No. 78950-78-4
Solubility (25°C)* 体外 DMSO 49 mg/mL (198.07 mM)
Ethanol 49 mg/mL (198.07 mM)
Water Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 8-OH-DPAT (8-Hydroxy-DPAT) is a kind of classic 5-HT1A agonist with the pIC50 of 8.19. It has a selectivity of almost-1000 fold for a subtype of the 5-HT1 binding site; Its biological half-life is 1.5 hous.
in vitro 8-OH-DPAT (8-Hydroxy-DPAT) is only weakly effective at the 5-HT1B subtype, with a pIC50 of 5.42 ± 0.08 (n = 5), and it has no effect on 5-HT1B binding at concentrations lower than 100 nM[1]. This compound is able to reduce the accumulation of both autophagic-derived and photoreceptor outer segment-derived lipofuscin, increase antioxidant protection and reduce oxidative damage in cultured human RPE cells[4].
in vivo The selective 5-HT1A-receptor agonist 8-OH-DPAT (8-Hydroxy-DPAT) rapidly reverses the hypotensive and bradycardic responses established during severe hemorrhage with relatively little variability when administered intravenously. It is relatively lipophilic and readily crosses the blood-brain barrier[3].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Retinal pigment epithelial (RPE) cells
濃度 10 μM
反応時間 24 h
実験の流れ

Cells are exposed to H2O2 (200 µM) for 1 hour and either pre-or post treated with 8-OH-DPAT (8-Hydroxy-DPAT) (10 µM) for 24 hours. In the case of pretreatment all measurements are made 24 hr after H2O2 and for post treatment it is added immediately following H2O2 exposure. 5HT1A agonist treatment: To assess the ability of the 5-HT1A receptor agonist to reduce lipofuscin formation in cultured RPE cells, this compound is added to the culture medium every 48 hours at concentrations ranging from 0.1 to 20 µM. All experiments are undertaken in basal medium, and cells receiving vehicle alone (PBS) acted as negative controls. To determine if the effect of this compound is sustained following discontinuation of 5-HT1A receptor agonist treatment, it is discontinued after 28 days and the cells maintained in basal medium or fed POS for a further 28 days. To assess its ability to remove existing lipofuscin, autophagy-derived lipofuscin and phagocytic-derived lipofuscin are allowed to accumulate as described above and then it is added every second day for up to 28 days. To confirm that it is acting via the 5-HT1A receptor agonist we include the 5-HT1A receptor antagonist S(-)-UH-301 at 5 µM in some experiments. To determine the effect of timing of treatment on oxidative stress markers, RPE cultures are either pre-treated with it (at 1 or 10 µM) for 3 or 24 hours prior to exposure to 200 µM H2O2 for 1 hour or treated with the 5HT1A agonist for 3 or 24 hours post-exposure to H2O2. Cells not exposed to oxidative stressor serve as a negative control, and cells exposed to oxidative stressor but not it serve as a positive control. Cells exposed to it only act as an additional control.
動物実験 動物モデル Male Lister hooded rats
投薬量 0, 3.0, 10, 100 and 300 μg/kg
投与方法 i.p.

参考

  • https://pubmed.ncbi.nlm.nih.gov/6223827/
  • https://pubmed.ncbi.nlm.nih.gov/1826841/
  • https://pubmed.ncbi.nlm.nih.gov/12611395/
  • https://pubmed.ncbi.nlm.nih.gov/22509307/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain [ Nat Neurosci, 2025, 28(11):2285-2295] PubMed: 41039182
Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension [ Gastroenterology, 2024, 167(5):993-1007] PubMed: 38906512

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。